Patents Assigned to Navigen, Inc.
  • Patent number: 11414442
    Abstract: Methods of treating vascular leak, vascular inflammation, angiogenesis, ocular disorders, and/or inflammatory disorders in a patient are provided. The methods can include administering an ADP-ribosylation factor 6 (ARF6) inhibitor to the patient. The present disclosure also relates to new chemical entities and pharmaceutical compositions including ARF6 inhibitors. The ARF6 inhibitor may be a prodrug of an ARF6 inhibitor.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 16, 2022
    Assignee: Navigen, Inc.
    Inventors: Ashok Bajji, Kirill Ostanin, Alan Mueller, Damon Papac
  • Patent number: 10849901
    Abstract: Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: December 1, 2020
    Assignees: Navigen, Inc., The University of Utah Research Foundation
    Inventors: Kirill Ostanin, Mark Shenderovich, Ashok Bajji, Christopher L. Cioffi, Neil Moss, Hariprasad Vankayalapati, Dean Li
  • Patent number: 10765754
    Abstract: Disclosed herein are compositions and methods for inhibiting respiratory syncytial virus (RSV) entry into a host cell. Also provided herein are methods of identifying a peptide that interacts with the N-trimer of RSV F protein.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: September 8, 2020
    Assignees: Navigen, Inc., University of Utah Research Foundation
    Inventors: Brett D. Welch, Michael S. Kay, Debra Muir Eckert, Rena McKinnon, Michael Thomas Jacobsen
  • Patent number: 10487121
    Abstract: Disclosed are D-peptide compositions and methods for inhibiting HIV entry into host cells.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 26, 2019
    Assignees: Navigen, Inc., University of Utah Research Foundation
    Inventors: Brett D. Welch, James Nicholas Francis, Michael S. Kay
  • Patent number: 10189878
    Abstract: Ebolavirus is a highly lethal filovirus that causes hemorrhagic fever in humans and non-human primates. With no approved treatments or preventatives, the development of an anti-ebolavirus therapy to protect against natural infections and potential weaponization is an urgent unmet global health need. The design, biophysical characterization, and validation of peptide mimics of the ebolavirus N-trimer (“N-trimer mimics”) are described herein.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: January 29, 2019
    Assignees: University of Utah Research Foundation, Navigen, Inc., The United States of America—Air Force
    Inventors: Tracy R. Clinton, Michael Thomas Jacobsen, Matthew T. Weinstock, Brett D. Welch, Debra Muir Eckert, Michael S. Kay
  • Publication number: 20170189405
    Abstract: Disclosed herein are compounds and methods for inhibiting Arf6. Pharmaceutical compositions and methods for treating a subject with an inhibitor of Arf6 are also disclosed herein.
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicants: Navigen, Inc., The University of Utah Research Foundation
    Inventors: Kirill Ostanin, Mark Shenderovich, Ashok Bajji, Christopher L. Cioffi, Neil Moss, Hariprasad Vankayalapati, Dean Li
  • Patent number: 9092391
    Abstract: The present invention provides methods of determining a Genetic Composite Index score by assessing the association between an individual's genotype and at least one disease or condition. The assessment comprises comparing an individual's genomic profile with a database of medically relevant genetic variations that have been established to associate with at least one disease or condition.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 28, 2015
    Assignee: Navigenics, Inc.
    Inventors: Dietrich A. Stephan, Melissa Floren Filippone, Jennifer Wessel, Michele Cargill, Eran Halperin
  • Publication number: 20140172444
    Abstract: The present disclosure provides methods and systems for personal action plans based on an individual's genomic profile. Methods include assessing the association between an individual's genotype and at least one disease or condition and providing rating systems for an individual's action plan. Incentives to motivate and encourage people to improve their health and well-being are also disclosed herein.
    Type: Application
    Filed: December 13, 2013
    Publication date: June 19, 2014
    Applicant: Navigenics, Inc.
    Inventors: Stephen M. MOORE, Michael A. NIERENBERG, Sean E. GEORGE, Laurie A. GOMER
  • Publication number: 20100070455
    Abstract: The present disclosure provides methods and systems for incorporating multiple environmental and genetic risk factors into an individual's genomic profile. Methods include assessing the association between an individual's genotype and at least one disease or condition by incorporating multiple genetic risk factors, environmental risk factors, or a combination of both.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 18, 2010
    Applicant: Navigenics, Inc.
    Inventors: Eran Halperin, Jennifer Wessel, Michele Cargill, Dietrich A. Stephan
  • Publication number: 20100042438
    Abstract: The present disclosure provides methods and systems for personal action plans based on an individual's genomic profile. Methods include assessing the association between an individual's genotype and at least one disease or condition and providing rating systems for an individual's action plan. Incentives to motivate and encourage people to improve their health and well-being are also disclosed herein.
    Type: Application
    Filed: August 7, 2009
    Publication date: February 18, 2010
    Applicant: Navigenics, Inc.
    Inventors: Stephen M. Moore, Michael A. Nierenberg, Sean E. George, Laurie A. Gomer